ABSTRACT Introduction: Dry powder inhalers (DPIs) are popular for pulmonary drug
delivery. Various techniques have been employed to produce inhalation drug particles and …

Respiratory infections represent a major global health problem. They are often treated by
parenteral administrations of antimicrobials. Unfortunately, systemic therapies of high-dose …

Dry powder inhaler (DPI) products have traditionally comprised a simple formulation of
micronised drug mixed with a carrier excipient, typically lactose monohydrate. The presence …

Dry powder inhalers (DPIs) offer distinct advantages as a means of pulmonary drug delivery
and have attracted much attention in the field of pharmaceutical science. DPIs commonly …

The efficacy of pharmaceutical aerosols relates to its deposition in the clinically relevant
regions of the lungs, which can be assessed by in vivo lung deposition studies. Dry powder …

Novel inhaled therapeutics including antibiotics, vaccines and anti-hypertensives, have led
to innovations in designing suitable delivery systems. These emerging design technologies …

Pulmonary drug delivery is the focus of much research and development because of its
great potential to produce maximum therapeutic benefit. Among the available options the dry …

Understanding interparticle interactions in powder systems is crucial to pharmaceutical
powder processing. Nevertheless, there remains a great challenge in identifying the key …

Orally inhaled products have well-known benefits. They allow for effective local
administration of many drugs for the treatment of pulmonary disease, and they allow for …

Dry powder inhalers have become increasingly attractive for pulmonary delivery of locally
and systemically effective medications. In comparison to the liquid counterparts, such as …